Carobbio, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.862
AS - Asia 5.521
EU - Europa 1.874
SA - Sud America 724
Continente sconosciuto - Info sul continente non disponibili 158
AF - Africa 87
OC - Oceania 12
Totale 14.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.651
CN - Cina 2.238
SG - Singapore 1.387
BR - Brasile 546
HK - Hong Kong 520
IT - Italia 506
VN - Vietnam 463
KR - Corea 425
GB - Regno Unito 317
FI - Finlandia 298
RU - Federazione Russa 163
BD - Bangladesh 151
FR - Francia 131
SE - Svezia 125
CA - Canada 107
AR - Argentina 84
ID - Indonesia 83
DE - Germania 64
IN - India 59
NL - Olanda 56
LT - Lituania 43
MX - Messico 43
PK - Pakistan 37
JP - Giappone 31
ZA - Sudafrica 30
ES - Italia 26
PL - Polonia 26
CO - Colombia 24
EC - Ecuador 24
IQ - Iraq 23
AT - Austria 22
JM - Giamaica 20
UA - Ucraina 20
CR - Costa Rica 14
CH - Svizzera 12
CL - Cile 12
MA - Marocco 12
TN - Tunisia 11
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
PY - Paraguay 10
GR - Grecia 9
NP - Nepal 9
TR - Turchia 9
AU - Australia 7
HN - Honduras 7
IE - Irlanda 7
PE - Perù 7
SA - Arabia Saudita 7
ET - Etiopia 6
KE - Kenya 6
PH - Filippine 6
VE - Venezuela 6
BO - Bolivia 5
EG - Egitto 5
HR - Croazia 5
JO - Giordania 5
MY - Malesia 5
RO - Romania 5
UY - Uruguay 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
DZ - Algeria 4
GE - Georgia 4
GT - Guatemala 4
IL - Israele 4
KZ - Kazakistan 4
SI - Slovenia 4
SV - El Salvador 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LB - Libano 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
AM - Armenia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
PT - Portogallo 2
SC - Seychelles 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
Totale 14.061
Salva come PNG Salva come JPEG
Città #
Hefei 1.544
Santa Clara 1.347
Singapore 768
Ashburn 726
San Jose 706
Hong Kong 514
Seoul 423
Council Bluffs 358
Helsinki 283
London 240
Ho Chi Minh City 184
Chicago 129
Milan 119
The Dalles 113
Los Angeles 105
Hanoi 98
Kent 91
Lauterbourg 90
Beijing 87
Boardman 70
Moscow 64
New York 61
Jakarta 58
Buffalo 52
Phoenix 49
Salt Lake City 47
Redondo Beach 46
Dallas 44
North Bergen 42
São Paulo 42
Brooklyn 40
Piscataway 40
Shanghai 39
Amsterdam 29
Secaucus 28
Atlanta 25
Da Nang 25
Nuremberg 23
Rome 23
Denver 21
Elk Grove Village 21
Rio de Janeiro 21
Plano 20
Tokyo 19
Warsaw 19
Salvador 18
Tampa 18
Frankfurt am Main 17
Houston 17
Newark 17
Curitiba 16
Johannesburg 16
Toronto 16
Haiphong 15
Karachi 15
Lansdowne 15
Montreal 15
Boston 14
Chennai 14
Miano 14
Brasília 13
Ealing 13
Florence 13
Guayaquil 13
Miami 13
Tianjin 13
Guangzhou 12
Orem 12
Campinas 11
Clifton 11
Dhaka 11
Lappeenranta 11
Las Vegas 11
Mexico City 11
Sunnyvale 11
Vienna 11
Washington 11
Austin 10
Baghdad 10
Columbus 10
Fort Lauderdale 10
Kingston 10
Padua 10
San Francisco 10
Seattle 10
Tashkent 10
Turin 10
Hillsboro 9
San José 9
Surrey 9
Assago 8
Bari 8
Biên Hòa 8
Chengdu 8
Cleveland 8
Dulles 8
Lahore 8
Ninh Bình 8
North Charleston 8
Paris 8
Totale 9.538
Salva come PNG Salva come JPEG
Nome #
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) 251
Masked polycythemia vera (mPV): results of an international study 233
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 220
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer 204
Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children 199
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms 194
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 193
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 184
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 183
Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study 175
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 171
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment 164
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 162
Long-term follow-up of recovered MPN patients with COVID-19 161
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study 158
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 155
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 152
Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response 151
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study 150
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 149
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists 149
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 147
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 146
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients 146
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study 145
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study 144
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis 142
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes 141
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study 141
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 141
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 139
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts 136
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status 135
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia 134
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 130
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis 130
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera 130
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study 129
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin 128
Thrombosis in primary myelofibrosis: incidence and risk factors 127
Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study) 127
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria 125
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 125
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia 124
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 123
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera 121
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke? 121
Masked polycythemia vera diagnosed according to WHO and BCSH classification 119
ASXL1 mutations in primary and secondary myelofibrosis 119
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 119
Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria 117
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials 116
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis 116
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 115
The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives 115
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 113
Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit 113
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis 113
Splanchnic Vein Thromboses associated with Myeloproliferative Neoplasms: an international, retrospective study on 518 cases 112
Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support 112
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis 111
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 111
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 111
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients 110
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial 110
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 110
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy 109
Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing 109
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status 109
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 109
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases 108
Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device 108
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 108
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology 107
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials 107
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review 105
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI) 105
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach 105
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma 105
ACE inhibitors and cytoreductive therapy in polycythemia vera 105
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 102
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 101
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study 101
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification 101
Second versus first wave of COVID-19 in patients with MPN 100
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients 100
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) 100
Second cancers in MPN : Survival analysis from an international study 98
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment 98
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria 97
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 97
Leukocytosis and risk stratification assessment in essential thrombocythemia 97
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera 96
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics 95
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 95
Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma 94
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? 94
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate? 93
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients 92
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis 91
Totale 12.838
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024415 0 0 0 0 0 0 0 210 37 17 64 87
2024/20253.911 40 25 28 270 745 769 220 47 405 144 592 626
2025/20268.140 703 728 1.034 1.089 391 423 988 291 845 602 540 506
2026/20271.772 418 414 604 336 0 0 0 0 0 0 0 0
Totale 14.238